Sep 13, 2019 - BMO Capital Markets issues rating change for INCY
Sep 11, 2019 - BMO Capital Markets issues rating change for INCY
Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Sep 05, 2019 - Oppenheimer issues rating change for INCY
Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Jun 05, 2019 - Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
May 30, 2019 - Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.